Clinical trial · Observational
The Importance of Muscle Function in Patients With Disseminated Bladder Cancer
NCT04144270CI-TRIAL-00041793unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study investigates if reduced muscle mass and muscle function predispose to poor completion of oncological treatment in patients with bladder cancer (including cancer of the renal pelvis, ureter and urethra) and if muscle mass and muscle function change during oncological treatment in these patients. It also evaluates biomarkers for sarcopenia.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Urinary Bladder Neoplasm | Bladder Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Evaluation of muscle mass and muscle function | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Included patients
- description
- One-arm study. All included patients will have muscle mass and muscle function evaluated
- interventionNames
- Other: Evaluation of muscle mass and muscle function
Primary outcomes (1)
- measure
- Muscle mass
- timeFrame
- Up to 36 months
- description
- We will describe if muscle mass at baseline is correlated to completion of planned systemic oncological treatment
Secondary outcomes (3)
- measure
- Muscle strength
- timeFrame
- Up to 36 months
- description
- We will describe if muscle strength at baseline is correlated to completion of planned systemic oncological treatment
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Informed consent * Age ≥ 18 år * Histologically verified cancer of the renal pelvis, ureter, bladder or urethra regardless of type of histology * ECOG performance status 0 - 3 * Meet the requirements for receiving oncological treatment (neoadjuvant chemotherapy for localized disease, chemotherapy or immunotherapy for disseminated disease). Exclusion Criteria: * Age \< 18
References
Publications (0)
Data not yet available
No reference posted for this study.